Related Experiment Video
Updated: May 14, 2026
23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
Developing dopaminergic cell therapy for Parkinson's disease--give up or move forward?
1Lund Stem Cell Center, University Hospital, Lund, Sweden. olle.lindvall@med.lu.se
Movement Disorders : Official Journal of the Movement Disorder Society
|February 13, 2013
Summary
Dopamine cell therapy for Parkinson's disease (PD) shows promise despite past challenges. Recent advances in stem cell technology and understanding graft mechanisms support its continued development for motor symptom relief.
Area of Science:
- Neuroscience
- Regenerative Medicine
- Cell Therapy
Background:
- Parkinson's disease (PD) lacks effective dopaminergic cell therapy despite decades of research.
- Previous attempts using fetal tissue faced challenges including efficacy, graft-induced dyskinesias, and disease progression.
- Key arguments against cell therapy include lack of efficacy, dyskinesias, graft destruction, and failure to address non-motor symptoms.
Discussion:
- Recent scientific advancements provide a strong rationale for continuing PD cell therapy development.
- Identified factors influencing transplantation outcomes enable optimization of cell survival and function.
- Improved understanding of graft-induced dyskinesias aids in mitigating adverse effects.
Key Insights:
- Stem cell technologies allow for the generation of large numbers of dopaminergic neurons for transplantation.
- Long-term motor recovery has been observed in patients with well-functioning grafts.
- Cell therapy can provide therapeutic motor benefits even when non-motor symptoms persist.
Outlook:
- Continued research into dopaminergic cell therapy holds significant potential for treating Parkinson's disease.
- Addressing challenges through scientific advancements can lead to more effective and safer cell-based treatments.
- Future strategies may focus on optimizing graft integration and managing both motor and non-motor symptoms.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:21EPS and iPS Cells in Disease Research
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...